Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24608
Abstract: The introduction of bortezomib has revolutionized the treatment of multiple myeloma (MM) and significantly improved outcomes in MM patients. Similar to many other chemotherapeutic agents, there are numerous reports of bortezomib-induced cardiotoxicity. Furthermore, the FDA… read more here.
Keywords: ixazomib; induced cardiotoxicity; proteasome inhibitors; treatment ... See more keywords
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-03985-9
Abstract: Ixazomib, the first oral proteasome inhibitor (PI), has been approved for the treatment of relapsed refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, based on the TOURMALINE-MM1 phase 3 trial, which demonstrated the… read more here.
Keywords: ixazomib; real world; trial; treatment ... See more keywords
Ixazomib-induced cutaneous necrotizing vasculitis
Sign Up to like & getrecommendations! Published in 2018 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-018-4052-1
Abstract: Ixazomib is a second-generation proteasome inhibitor that has been approved in the combination treatment of multiple myeloma and is currently under clinical investigation for the management of Waldenstrom’s macroglobulinemia. While cutaneous adverse events secondary to… read more here.
Keywords: ixazomib; vasculitis; induced cutaneous; necrotizing vasculitis ... See more keywords
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Sign Up to like & getrecommendations! Published in 2019 at "ESMO Open"
DOI: 10.1136/esmoopen-2019-000570
Abstract: On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have… read more here.
Keywords: ixazomib; received least; multiple myeloma; myeloma received ... See more keywords
Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-10-811620
Abstract: Introduction: Granulocyte colony-stimulating factor (G-CSF) is the most commonly used drug for stem cell mobilization. Unfortunately, 5-30% of patients fail to collect sufficient hematopoietic stem/progenitor cells (HSPCs) to proceed to transplant. New strategies are needed… read more here.
Keywords: ixazomib; administration; proteasome inhibitor; progenitor cells ... See more keywords
A Systematic Review and Meta-Analysis: Efficacy and Toxicity Profile of Ixazomib for Treatment of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-117159
Abstract: Background: Ixazomib (Ixa) is the first FDA approved oral proteasome inhibitor to be used for relapsed and refractory multiple myeloma (MM). We conducted a comprehensive systematic review and meta-analysis of all published prospective clinical trials… read more here.
Keywords: ixazomib; analysis; efficacy; multiple myeloma ... See more keywords
Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124354
Abstract: Inhibition of the ubiquitin-proteasome proteolytic pathway results in extensive immunomodulatory effects, augmenting NK cell cytotoxicity while inhibiting aspects of T-, B- and dendritic cell function. To this end, short course bortezomib has been utilized post-transplant… read more here.
Keywords: ixazomib; gvhd; cell; post transplant ... See more keywords
Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.8013
Abstract: 8013Background: The proteasome inhibitor (PI) ixazomib (Ixz) is the first orally administered PI approved for treating multiple myeloma (MM). It has shown clinical activity as a single agent and wh... read more here.
Keywords: relapsed refractory; ixazomib; multiple myeloma; ixazomib relapsed ... See more keywords
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14205165
Abstract: Simple Summary We report the final outomes of the addition of ixazomib to the combination of lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma in the routine clinical practice. With prolonged follow-up,… read more here.
Keywords: ird; ixazomib; relapsed refractory; myeloma ... See more keywords